The study concerns patients with Invasive epithelial ovarian cancer, primary Fallopian tube carcinoma, ovarian-type peritoneal carcinoma, and with an indication of a first-line platinum-based chemotherapy.

To determine HRD status, 2 separate tests will be performed in the study:

1. Giscar assay : developed by the sponsor
2. myChoice assay

If one or two tests identifies a HRD status :

a PARP inhibitor treatment may be initiated according to current recommendations

Inclusion Criteria:

• Patient aged 18-year or more

• Histologically documented high grade serous epithelial ovarian cancer, fallopian tube or peritoneum cancer

• Newly diagnosed advanced (International Federation of Gynecology and Obstetrics [FIGO] stage III or IV) ovarian carcinoma, candidate to a first line platinum-based chemotherapy

• Tumor tissue must be available for HRD analyses (FFPE tissue block) and

  • Collected if possible during the initial surgery or the initial biopsy (before chemotherapy)
  • With sufficient tumour surface area (> 25 mm²), with a final cellularity of at least 20%

• Patient affiliated to an appropriate social security system

• Patient signed consent form before any trial related activities

Exclusion Criteria:

• Recurrent high grade serous epithelial ovarian cancer, fallopian tube or peritoneum cancer
• Non epithelial or borderline ovarian cancer
• Other tumor, for which the treatment may interfere with the ovarian cancer treatment and/or that may have a major impact on prognosis
• Exclusive palliative setting
• Patient deprived of liberty or placed under the authority of a tutor